The FDA approved Novo Nordisk’s oral semaglutide formulation, marking the first pill version of Wegovy authorized for chronic weight management and cardiovascular risk reduction. The decision follows phase 3 data showing robust efficacy — the highest-dose cohort recorded roughly 16.6% mean weight loss at 64 weeks versus placebo — and positions Novo to expand access beyond injectables. Clinicians and payers will now evaluate how oral dosing, tolerability and cost alter real-world uptake compared with weekly injectables. Trials cited by Novo Nordisk and independent endocrinologists reported similar safety profiles to subcutaneous semaglutide, with gastrointestinal side effects the most frequent adverse events. Regulators cleared the indication for adults with obesity and for cardiovascular risk reduction as in the injectable label. The launch timing and formulary negotiations will determine whether the pill meaningfully broadens patient access and shifts market dynamics among GLP-1 makers. For readers: oral GLP-1s aim to replicate injectable efficacy while improving convenience; they often require dosing conditions (eg, empty stomach) that affect adherence and pharmacokinetics.